Loading
Life sciences · Journal article
Drug and Alcohol Dependence Reports · September 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
This narrative review reconstructs the U.S. history of treating co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) from the rise of methadone maintenance in the 1960s through contemporary interest in immunometabolic mechanisms and repurposed therapies. Drawing on peer-reviewed literature and selected grey sources, we trace four eras including early single-substance paradigms and maintenance; federally regulated opioid treatment programs and the broader medicalization of addiction care; recognition of co-occurring disorders, parity and Affordable Care Act reforms, and uneven diffusion of medications for OUD and AUD; and a renewed metabolic framing, including preclinical, clinical, and real-world evaluation of glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonists. Across eras, regulation, reimbursement, and professional authority shaped access as much as evidence, producing persistent geographic and socioeconomic inequities. Emerging GLP-1-based therapies may offer a distinctive cross-disorder adjunct, but their value for OUD/AUD remains unproven. Population benefit will require rigorous trials and delivery reforms that expand equitable access to integrated care.